The CSL Limited (ASX: CSL) share price used to be one of the most seemingly bulletproof investments on the ASX. For years and years, it seemed CSL shares could only go up. And this was true for a time. CSL spent eight years from 2012 to 2020 rising from around $30 to over $300, finally topping out at roughly $336 a share in February 2020.
But the past three years have been a very different story for CSL shares. Since reaching the all-time high of $336 a share in February 2020, CSL has yet to reclaim that high. In fact, the company is today sitting at just over $273 a share at the time of writing. That’s a good 19% or so away from CSL’s high watermark. The first time CSL hit $270 a share, it was back in late 2019. That means that for almost three years, CSL shares have been stuck in the mud. On today’s pricing, the company remains down by 6.5% over the past 12 months, and down close to 8% in 2022 so far.
So is it winner to loser for CSL? Or does this meandering share price performance give investors a compelling buy case for CSL today?
Are CSL shares a buy today?
Well, ASX broker Citi reckons it’s the latter. As my Fool colleague James covered last week, Citi is currently a fan of CSL shares. It has given the ASX 200 healthcare giant a buy rating and a 12-month share price target of $335 – back to its old all-time high. The broker reckons that CSL will continue to benefit from improved plasma collections and “strong underlying demand” for its products.
But Citi isn’t the only fan of CSL shares right now. My Fool colleague Tony covered an ASX fund manager’s opinion on CSL this morning, and it was also a bullish one. Catapult Wealth portfolio manager Tim Haselum named CSL as one of the two ASX shares he reckons is a best buy now. Haselum pointed to CSL’s “lifesaving and non-discretionary nature”, as well as its track record in making lucrative acquisitions, for this optimism.
So that’s how two ASX expert investors are viewing CSL shares right now. The CSL share price has been stuck in the mud for a few years. But if these two investors are to be believed, it might just hit the road again soon.
At the current CSL share price, this ASX 200 healthcare share has a market capitalisation of $131.56 billion, with a dividend yield of 0.95%.
The post After being stuck in the mud for 3 years, are CSL shares a buy today? appeared first on The Motley Fool Australia.
Should you invest $1,000 in CSL right now?
Before you consider CSL, you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and CSL wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of January 13th 2022
More reading
- The best 2 ASX shares money can buy right now: expert
- ASX shares paid out a record $98b in dividends in the 12 months to March. Which are the star performers?
- Why has the CSL share price lagged the ASX 200 over the past week?
- 2 top blue chip ASX 200 shares to buy now according to experts
- Why I would invest $10,000 into these ASX shares today
Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
from The Motley Fool Australia https://ift.tt/xWaUPNf
Leave a Reply